Companies › STCube
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nelmastobart BTN1A1 agonist | BTN1A1 | Phase 2 | Non Small Cell Lung Cancer; Metastatic Colorectal Cancer (CRC) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06873763 | Nelmastobart | Phase 1 | Metastatic Colorectal Cancer (CRC) | Oncology | Mar 2027 |
| NCT07306624 | Nelmastobart | Phase 2 | Non Small Cell Lung Cancer | Oncology | Aug 2027 |
–
CrystalGenomics Partner Therapeutics Ambrx Convergent Therapeutics I-Mab Biopharma US
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.